Cubic phases for studies of drug partition into lipid bilayers.
Drug partition into lipid bilayers in a cubic liquid-crystalline phase was investigated. Glyceryl monooleate was used to form the lipid bilayer in a reversed bicontinuous cubic liquid-crystalline phase. The reason for using the cubic phase is that it may coexist with an external aqueous phase, and that the phase boundary (cubic phase/aqueous bulk) is well-defined due to the stiffness of the cubic phase. This makes the cubic phase a potential candidate for high throughput screening (HTS) of the lipophilicity and the dissociation constant (if any) of drug compounds. Clomethiazole (CMZ), lidocaine, prilocaine and 4-phenylbutylamine (4-PBA) were chosen as model drug compounds. It was shown that it is possible to determine a pH-dependent apparent partition coefficient, Kbl/w, of a drug compound using a lipid bilayer expressed as a cubic liquid-crystalline structure. Good agreement was found when the resulting Kbl/w vs. pH curves for CMZ, lidocaine and prilocaine were fitted to a mathematical expression. This included the bilayer/water partition coefficient for the unionised and ionised drug respectively and the pKa of the drug. The effect of different experimental conditions; such as amount of cubic phase, temperature, agitation, sample preparation and interfacial area between the cubic phase and the aqueous bulk on the partition kinetics were investigated as well. The studies reveal that the time needed to reach partition equilibrium was, as expected, substantially reduced (from days to hours) by decreasing the amount of cubic phase, increasing the interfacial area between the cubic phase and the aqueous phase, and increasing the temperature and the agitation of the sample. It was also shown that the bilayer affinity of 4-PBA was increased when a zwitterionic lipid (i.e. dioleoyl phosphatidylcholine, DOPC) was incorporated in the bilayer.
Engström
S
S
Food Technology, Lund University, Box 124, SE-221 00, Lund, Sweden. sven.engstrom@livsteki.lth.se
Nordén
T P
TP
Nyquist
H
H
D000779:Anesthetics, Local / Q000493:pharmacokinetics; D002082:Butylamines / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002719:Chlormethiazole / Q000493:pharmacokinetics; D005989:Glycerides / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008012:Lidocaine / Q000493:pharmacokinetics; D008051:Lipid Bilayers / Q000737:chemistry* / Q000378:metabolism*; D000442:Octanols / Q000737:chemistry; D010713:Phosphatidylcholines / Q000737:chemistry; D011318:Prilocaine / Q000493:pharmacokinetics; D012995:Solubility; D014867:Water / Q000737:chemistry; D014961:X-Ray Diffraction
C121358:4-phenylbutylamine; D000779:Anesthetics, Local; D002082:Butylamines; D005989:Glycerides; D008051:Lipid Bilayers; D000442:Octanols; D010713:Phosphatidylcholines; D011318:Prilocaine; D014867:Water; D002719:Chlormethiazole; D008012:Lidocaine; C005953:monoolein; C017251:1,2-oleoylphosphatidylcholine